Apoptosis: Mediator or mode of cell killing by anticancer agents?

Drug Resistance Updates

Volumn 4, Issue 2, 2001, Pages 135-136

  Brown, J Martin ^a   Wouters, Bradly G ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ETOPOSIDE; PROTEIN P53;

APOPTOSIS; CANCER THERAPY; CELL DEATH; CELL KILLING; DNA DAMAGE; HEREDITY; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; WHOLE BODY RADIATION;

EID: 0034931001     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2001.0193     Document Type: Short Survey

References (9)

1. Apoptosis, p53, and tumor cell sensitivity to anticancer agents
2. Does tumor cell resistance to apoptosis affect the outcome of chemotherapy?
3. Programmed cell death is critical for drug response in vivo
4. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53
5. Prognostic and predictive significance of p53 mutation in aggressive B-cell lymphoma
6. Computerized video time-lapse analysis of apoptosis of REC: Myc cells X-irradiated in different phases of the cell cycle
7. p53 induction and apoptosis in response to radio-and chemotherapy in vivo is tumor-type-dependent
8. p53 is required for radiation-induced apoptosis in mouse thymocytes
9. Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors